The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $32.43

Today's change+0.51 +1.60%
Updated July 20 4:03 PM EDT. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $32.43

Today's change+0.51 +1.60%
Updated July 20 4:03 PM EDT. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd crosses above 125-day moving average

Teva Pharmaceutical Industries Ltd closed up sharply Thursday, rallying (U.S.)$0.51 or 1.60% to (U.S.)$32.43 and crossing above its 125-day moving average. Over the last five days, shares have lost 2.29% and are down 10.54% for the last year to date. This security has underperformed the S&P 500 by 54.82% during the last year.

Key company metrics

  • Open(U.S.) $32.12
  • Previous close(U.S.) $31.92
  • High(U.S.) $32.74
  • Low(U.S.) $32.03
  • Bid / Ask-- / --
  • YTD % change-10.54%
  • Volume5,753,562
  • Average volume (10-day)8,412,860
  • Average volume (1-month)7,507,645
  • Average volume (3-month)7,311,497
  • 52-week range(U.S.) $27.60 to (U.S.) $55.79
  • Beta0.46
  • Trailing P/E306.96×
  • P/E 1 year forward6.72×
  • Forward PEG7.48×
  • Indicated annual dividend(U.S.) $1.36
  • Dividend yield4.19%
  • Trailing EPS(U.S.) $0.11
Updated July 20 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+1.31%

Based on its net profit margin of 1.31%, Teva Pharmaceutical Industries Ltd is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.13%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue5,6306,4925,5635,038
Total other revenue--------
Total revenue5,6306,4925,5635,038
Gross profit2,8193,3902,8012,877
Total cost of revenue2,8113,1022,7622,161
Total operating expense4,7356,6294,7984,677
Selling / general / administrative1,2071,4401,2501,263
Research & development457684663375
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)2051,508720792
Other operating expenses, total3-105-59786
Operating income895-137765361
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax688-914615256
Income after tax634-971408227
Income tax, total545720729
Net income645-973412254
Total adjustments to net income-65-65-64-66
Net income before extra. items645-973412254
Minority interest41212
Equity in affiliates7-3215
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items580-1,038348188
Inc. avail. to common incl. extra. items580-1,038348188
Diluted net income580-1,038348188
Dilution adjustment0000
Diluted weighted average shares1,0171,015984920
Diluted EPS excluding extraordinary itemsvalue per share0.57-1.020.350.20
Dividends per sharevalue per share0.340.340.340.34
Diluted normalized EPSvalue per share0.76-0.060.840.97